ERS Genomics secures EPO CRISPR victory
ERS Genomics has successfully defended one of its EU patents covering CRISPR-Cas9 gene editing technologies, after the European
Patent Office (EPO) rejected arguments filed in opposition to the patent.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.